Mostrando entradas con la etiqueta LABAs. Mostrar todas las entradas
Mostrando entradas con la etiqueta LABAs. Mostrar todas las entradas

4 de agosto de 2015

(COCHRANE): En un paciente con asma bien controlado con LABA + Corticoides inhalados ¿se debe suspender el LABA?


(COCHRANE) En un paciente con asma bien controlado con LABA + Corticoide inhalado ¿se debe suspender el LABA?

Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids

http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011306.pub2/abstract

Authors' conclusions

This review suggests that stopping LABA in adults who have stable asthma while they are taking a combination of LABA and ICS inhalers may increase the likelihood of asthma exacerbations that require treatment with oral corticosteroids, but this is not certain. Stopping LABA may slightly reduce asthma control and quality of life, but evidence was insufficient to show whether this had an effect on important outcomes such as serious adverse events and exacerbations requiring hospital admission, and longer trials are warranted. Trialists should include patient-important outcomes such as asthma control and quality of life and should use validated measurement tools. Definitions of exacerbations should be provided.

16 de agosto de 2011

Triple terapia en EPOC

Efectos sobre la mortalidad y exacerbaciones
The impact of Tiotropium on Mortality and Exacerbations when added to Inhaled Corticosteroids and Long-Acting Beta-Agonist therapy in COPD